A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer

Trial Profile

A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2015

At a glance

  • Drugs Tergenpumatucel-L (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Jun 2013 Results from the phase II part were presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), and were reported in a NewLink Genetics Corporation media release.
    • 04 Jun 2012 Thirty-seven patients were enrolled in the phase II part, and 28 of these were evaluable for response analysis, according to a NewLink Genetics media release.
    • 04 Jun 2012 Results were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), and in a NewLink Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top